Please login to the form below

Not currently logged in
Email:
Password:

Merck Serono names R&D head

Luciano Rossetti replaces Annalisa Jenkins
merck-Rossetti

Merck Serono yesterday announced Luciano Rossetti as its new global head of R&D effective July 21, 2014.

Rossetti replaces Annalisa Jenkins who left Merck Serono, the biopharma division of Germany-based Merck KGaA, in March this year to move to the US. She spent just under three years in the role having moved to Merck from Bristol-Myers Squibb.

Rossetti joins Merck Serono from its US-based namesake Merck & Co, known as MSD outside the US. He was senior VP, late stage development at Merck & Co, holding responsibility for clinical development from phase II to phase V across all therapy areas.

In this role he was influential in shaping the development strategy of Merck & Co's promising anti-PD1 therapy pembrolizumab. Prior to joining Merck & Co in 2006, Rossetti had been an academic scientist for 18 years,

Belén Garijo, who was appointed CEO at Merck Serono last year, said she was “thrilled' to have Rossetti join the team.

She said: “His breadth of experience and solid track record in both research as well as development together with his distinct leadership profile will be instrumental in driving the development of our promising pipeline to ensure that we will meet our strategic milestones and deliver innovative solutions for unmet medical needs to patients around the world.”

15th July 2014

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics